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arrest and apoptosis in endometriosis cells
Pietro G Signorile*, Francesca Petraglia and Alfonso Baldi*Abstract
Background: The anti-mullerian hormone (AMH) is a member of the transforming growth factor β (TGF-β) superfamily,
which is responsible of the regression of the mullerian duct. AMH is expressed in the normal endometrium, where,
acting in a paracrine fashion, negatively regulates cellular viability. Our objective was to evaluate the in vitro effects of
the treatment with AMH of endometriosic cells.
Methods: AMH expression in human endometriosis glands was evaluated by immunohistochemistry. RT-PCR has been
used to quantify the expression levels of AMH and AMH RII isoforms, as well as of cytochrome P450 in both endometriosis
epithelial and stromal cells Effects of AMH and AMH-cleaved treatment in endometriosis cells were evaluated by
flow-cytometry analysis. Finally, it has been evaluated the effect of plasmin-digested AMH on cytochrome P450 activity.
Results: AMH and AMH RII isoforms, as well as cytochrome P450, were expressed in both endometriosis epithelial and
stromal cells. Treatment of endometriosis stromal and epithelial cell growth with AMH was able to induce a decrease in
the percentage of cells in S phase and increase percentage of cells in G1 and G2 phase; coherently, decreased cell
viability and increased percentage of cells death fraction was observed. The plasmin-digested AMH was able to suppress
most of the cytochrome P450 activity, causing an increase of pre-G1 phase and of apoptosis induction treating with
plasmin-digested AMH in both cell lines, most marked in the epithelial cells.
Conclusions: The data produced suggest a possible use of AMH as therapeutic agents in endometriosis.
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Endometriosis is a gynaecological disease defined by the
histological presence of endometrial glands and stroma
outside the uterine cavity. Most commonly, endometrial
structures are implanted over visceral and peritoneal
surfaces, but rarely also in the pericardium, pleura, and
even brain [1]. The prevalence in the general female
population is 6-10%; in women with pain, infertility or
both, the frequency increases to 35-60% [2]. Endometriosis
is usually associated with infertility and pelvic pain such as
chronic dysmenorrhea, intermestrual abdominal and pel-
vic pain, back pain, dysuria, dyschezia and dyspareunia [3].
Moreover, it is often associated with a decrease of ovarian
reserve and reduction of ovarian volume [4]. Despite the
fact that this disease is quite common among women, it is* Correspondence: research@endometriosi.it; alfonsobaldi@tiscali.it
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unless otherwise stated.frequently misdiagnosed, the pathogenesis is unknown and
the diagnostic and therapeutic protocols are still not fully
adequate [1,3]. Currently, none of the pathogenetic theor-
ies proposed, such as retrograde menstruation, coelomic
metaplasia or staminal cells, has definitively been proved
[1]. Interestingly, our research group has recently demon-
strated the presence of endometrial implants outside the
uterus in a significant number of female human fetuses,
thus demonstrating that alterations in the fine-tuning of
the primitive mullerian tube formation is one of the causes
of endometriosis [5-9].
The anti-mullerian hormone (AMH) is a homodimeric
glycoprotein member of the transforming growth factor β
(TGF-β) superfamily, which is secreted by Sertoli cells in
the embryonic testes and is responsible of the regression
of the mullerian duct [10]. In the female fetus ovarian
granulosa cells begin to secrete low levels of AMH startingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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puberty to approximately 5-8 ng/mL but then gradually
decline throughout reproductive life until they become
undetectable by menopause. Therefore, AMH levels are
considered good indicators of the ovarian reservoir [11].
Recent studies have demonstrated that AMH, as well as
AMHRII (one of its receptors), are expressed in the adult
female also in the endometrium, where, probably, act in a
paracrine fashion and that negatively regulates cellular
viability in the endometrium [12].
Leaving from this background, we decided to deeply in-
vestigate the potential role of AMH in regulating cell viabi-
lity and proliferation of endometriosis cells, taking advantage
of an in vitro model of epithelial and stromal endometriosis
cells, recently generated in our laboratory [13].Methods
Patients and tissue samples
Retrospective evaluation was performed on surgical speci-
mens from 30 patients who underwent surgery for infertil-
ity, pelvic pain symptoms (including dysmenorrhea, deep
dyspareunia and no-menstrual pain) or adnexal masses be-
tween 2009 and 2012 at the “Centro Italiano Endometriosi”
in Rome and that were diagnosed with deep infiltrating
endometriosis. Representative sections of each specimen
were stained with haematoxylin-eosin to confirm the
diagnosis of endometriosis. For immunohistochemistry 5-
7 μm specimen sections embedded in paraffin, were cut,
mounted on glass and dried overnight at 37°C. All sections
were then deparaffinized in xylene, rehydrated through a
graded alcohol series and washed in phosphate-buffered
saline (PBS). PBS was used for all subsequent washes and
for antiserum dilution. Tissue sections were quenched
sequentially in 3% hydrogen peroxide in aqueous solution
and blocked with PBS-6% non-fat dry milk (Biorad,
Hercules, CA, U.S.A.) for 1 h at room temperature. Slides
were then incubated at 4°C overnight at 1:100 dilution with
a rabbit polyclonal antibody for AMH (Abcam, Cambridge,
UK). After three washes in PBS to remove the excess of
antiserum, the slides were incubated with diluted goat
anti-rabbit biotinylated antibody (Vector Laboratories,
Burlingame, CA, U.S.A.) at 1:200 dilution in PBS-3% non-
fat dry milk (Biorad) for 1 h. All the slides were then proc-
essed by the ABC method (Vector Laboratories) for
30 min at room temperature. Diaminobenzidine (Vector
Laboratories) was used as the final chromogen and
hematoxylin was used as the nuclear counterstain. Nega-
tive controls for each tissue section were prepared by
leaving out the primary antiserum. All samples were pro-
cessed under the same conditions. Experiments were
performed in compliance with the Helsinki Declaration
and the protocols were approved by the ethics committee
of the Fondazione Italiana Endometriosi.Cell lines and primary cells
Human endometriosis stromal and epithelial cells were
described elsewhere [13]. Cells were grown following
standard procedures and were propagated in DMEM/
F12 (1:1) with 10% Fetal Bovine Serum (FBS) (Gibco,
Life Technologies Italia, Monza, Italy), 2 mM L-Glutamine
(Euroclone S.p.a, Piero, Italy) and antibiotics (100 U/mL
penicillin, 100 μg/mL streptomycin and 250 ng/mL
amphotericin-B).
In vitro treatment with AMH
Cultured human endometrial stromal and epithelial cells
were treated with Recombinant Human Mullerian-
Inhibiting Substance (rhMIS)/anti-Mullerian hormone
(AMH) - E-Coli derived (R&D Systems) and Purified
recombinant protein of Homo sapiens AMH (OriGene
Technologies, Rockville, MD, USA) at three different
final concentrations (10-100-1000 ng) for three different
time (24-48-72 hrs). Plasmin-cleaved AMH was used
instead of the full-length molecule for incubation times
indicated. AMH was digested by Plasmin from human
plasma (Sigma-Aldrich, Italia) 1 h at 37°C in a ratio of
25 to 1, as described [14]. The effect of AMH on the
activity of cytochrome P450 aromatase (CYP19) was
measured through the P450-Glo assays (Promega Italia,
Milano, Italy) [15].
Cell vitality
Experiments were performed in duplicate. Cells were di-
luted 1:1 in Trypan blue (Sigma-Aldrich, Italia) and
counted.
Cell cycle and cell death
Analysis was performed in duplicate. 100.000 cells were
re-suspended in the staining solution containing RNAse
A, Propidium Iodide (PI) (50 mg/mL), sodium citrate
(0.1%), and NP40 (0.1%) in PBS 1X for 30 min in the
dark and room temperature. Cell cycle distribution was
assessed with an FACScalibur flow cytometer (Becton
Dickinson), and 10,000 cells were analyzed by ModFit
version 3 Technology (Verity) and Cell Quest (Becton
Dickinson) [16].
RNA, RT-PCR
Total RNA was extracted with TRIzol (Life Technologies)
and converted into cDNA using SuperScript VILO kit
according to the manufacturer’s protocol. (Invitrogen).
Converted cDNA was amplified using EuroTaq (Euroclone).
Amplified DNA fragments were loaded on 2.0% agarose gel
and photographed on a Gel Logic 200 Imaging system UV
transilluminator (Kodak). Levels of AMH, AMH type II
Receptor (AMHR-II) and CYP19 expression were quantified
by Reverse Transcription Polymerase Chain Reaction (RT-
Figure 1 Immunohistochemical expression of AMH in endometriosis tissues. (A) AMH expression in the epithelium of an endometriosis
gland (Original magnification X20). (B) The immunohistochemical expression of AMH is clearly visible also in the stromal cells of the endometriosis
gland (Original magnification X20).
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Green Supermix (Bio-Rad) in a DNA Engine Opticon2 ther-
mal cycler (MJ Research Incorporated). Primers: AMH gene
(1) (Forward 5′-CAC CCG CTA CCT GGT GTT AG-3′,
Reverse 5′-GGT CAT CCG TGT GAA GCA G-3′). AMHFigure 2 Effects of recombinant human Mullerian-inhibiting substanc
epithelial cell line. (A) pre-G1 fraction analysis of endometriosis epithelial
MIS. The data are shown in a time-dependent manner. (B) pre-G1 fraction
with the indicated final concentrations of MIS. The data are shown in a do
cells treated 24-48-72 hrs with the indicated final concentrations of MIS. Th
of endometriosis epithelial cells treated 24-48-72 hrs with the indicated final cgene (2) (Forward 5′-AAG CTG CTC ATC AGC CTG
TC-3′, Reverse 5′-TGG GGT CCG AAT AAA TAT GG-
3′). AMHR-II gene (1) (Forward 5′-CCC TGC TAC AGC
GAA AGA AC-3′, Reverse 5′-ATG GCA ACC AGT TTT
CCT TG-3′). AMHR-II gene (2) (Forward 5′-AAC TGGe (MIS)/anti-Mullerian hormone (E.Coli derived) on endometriosis
cells treated for 24-48-72 hrs with the indicated final concentrations of
analysis of endometriosis epithelial cell line treated for 24-48-72 hrs
se-dependent manner. (C) Cell cycle analysis of endometriosis epithelial
e data are shown in a time-dependent manner. (D) Cell cycle analysis
oncentrations of MIS. The data are shown in a dose-dependent manner.
Figure 3 Effects of recombinant human Mullerian-inhibiting substance (MIS)/anti-Mullerian hormone (E.Coli derived) on endometriosis
stromal cell line. (A) pre-G1 fraction analysis of endometriosis stromal cells treated for 24-48-72 hrs with the indicated final concentrations of
MIS. The data are shown in a time-dependent manner. (B) pre-G1 fraction analysis of endometriosis stromal cell line treated for 24-48-72 hrs with
the indicated final concentrations of MIS. The data are shown in a dose-dependent manner. (C) Cell cycle analysis of endometriosis stromal cells
treated for 24-48-72 hrs with the indicated final concentrations of MIS. The data are shown in a time-dependent manner. (D) Cell cycle analysis of
endometriosis stromal cells treated for 24-48-72 hrs with the indicated final concentrations of MIS. The data are shown in a dose-dependent manner.
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CCC AAC AGT CT-3′). GAPDH gene (Forward 5′-GGA
GTC AAC GGATTT GGT CGT-3′, Reverse 5′-GCT TCC
CGT TCT CAG CCT TGA-3′).Results
Histologic examination of endometriosis lesions of the
rectovaginal septum showed the typical presence of both
endometriotic glands and stroma. Immunohistochemical
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component expressed significant levels of AMH. Figure 1
depicts some exemplary cases of the immunohistochemical
staining for AMH in cases of endometriosis of the rectova-
ginal septum.
We were able to demonstrate the effects induced by
Recombinant Human Mullerian-Inhibiting Substance
(rhMIS)/anti-Mullerian hormone (AMH)E. Coli derived
on endometriosis stromal and epithelial cell growth, cell
cycle progression and apoptosis induction. We have
treated cultured human endometriosis stromal and
epithelial cells with rhMIS at different concentrations
(10-100-1000 ng/mL) and analyzed the effects induced
after 24-48-72 hours of treatment.
To investigate the various phases of the cell cycle, the
Flow Cytometer FACS (Fluorescent Activated Cell Sorter)
was used. The results shown were obtained using the Cell
Quest software (Becton Dickinson) and are shown in a
dose and time dependent manner to better visualize the
effect induced by treatment (Figure 2). As depicted in
Figure 2A and B, induction of cell death was present upon
treatment in a time and dose dependent manner. Despite
weak, this apoptotic effect was fully reproducible and spe-
cifically connected to the hormone treatment. The changes
in cell cycle distribution after 24 hours of AMH exposure
suggested that AMH plays an important role in inducing
an initial increase in the percentage of cells in the S phase,
which is translated into a G1 block at 48 hrs. Interestingly,
while the effects on apoptosis are dose and time
dependent, the cell cycle effects seem only time dependent
(Figure 2C-D). The results of high-AMH concentrations
treatment have confirmed a decreased percentage of cells
in S phase with increased percentage of cells in G1 and G2
phase (Figure 2D) and increasing local AMH concentration
in cultured human endometriosis stromal cells decreasedFigure 4 Effects of purified recombinant protein of Homo Sapiens an
(A) Cell cycle analysis of endometriosis stromal cells treated for 48 hrs with
stromal cells treated for 48 hrs with AMH at 1000 ng/mL.cell viability and increased percentage of cells death frac-
tion also (Figure 2A-B).
These effects where fully confirmed by using the stromal
cells (Figure 3). Despite slightly more resistant, in these
cells the apoptosis induced by the hormone was time and
dose dependent, whereas the cell cycle effects were only
time dependent.
Similarly, the Purified recombinant protein of Homo sa-
piens AMH treatment (10-100-1000 ng for 24-48-72 hours)
on endometriosis stromal cells line resulted in coherent re-
sults (Figure 4A-B). A small decrease in percentage of cells
in S and G2/M phases was observed (Figure 4A) with a
concomitant increase of cells in pre-G1 phase (Figure 4 B).
Various semi-quantitative RT-PCR have been used to
quantify the expression levels of AMH and AMH RII
isoforms in both endometriosis epithelial and stromal
cells (Figure 5A). The two isoforms analyzed were
designed with the Primer3 software. Both endometriosis
epithelial and stromal cells expressed mRNA for AMH
and AMH RII (Figure 5A). Finally, the expression levels
of CYP19 were confirmed through real-time PCR ana-
lysis (Figure 5B).
Considering that the plasmin-digested AMH has been
reported to be more active in cultured human endometrial
cell lines [15], human plasmin was used to cleave and acti-
vate the recombinant Human AMH at its monobasic
arginine-serine site at residues 427-428 and then tested in
functional experiments on both endometriosis stromal
and epithelial cells. Firstly, we found that plasmin-digested
AMH can alter the expression or function of CYP19,
evaluated by testing CYP19 activity. The results suggest
that the plasmin-digested AMH was able to suppress most
of the CYP19 activity. When the plasmin-digested AMH
was used on both endometriosis stromal and epithelial
cells (Figure 6), an increase of pre-G1 phase treating withti-Mullerian hormone (AMH) on endometriosis stromal cell line.
AMH at 1000 ng/mL. (B) pre-G1 fraction analysis of endometriosis
Figure 5 Analysis of AMH, AMHRII expression and CytP450 activity. (A) Real-time PCR to assess the percentage of expression levels of AMH
(1), AMH (2), AMH type II Receptor (1) and (2) (AMH RII) genes in endometrial epithelial and stromal cell line respectively. (B) Expression levels of
the Cytochrome P4501 and 2 isoforms and Reverse Transcriptase–Polymerase Chain Reaction (RT-PCR) for the CytP (450) 1 and 2 in epithelial and
stromal cell line respectively; GAPDH represents loading control. (C) CYP Activity assay in endometrial stromal cells treated for 24 hrs at 1000 ng/mL
of MIS full-length. (D) CYP Activity assay in endometrial stromal cells treated for 24 hrs at 1000 ng/mL of Plasmin-cleaved MIS.
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most marked in the epithelial cells (Figure 6). Also the
effect on induction of apoptosis was stronger during the
first 24 hours of treatment (Figure 6A-B). Interestingly,
and differently from the previous experiments, apoptosis
decreased after the 24 hrs, suggesting that, possibly, the
cleaved AMH is more unstable than the full-length pro-
tein. These results are also supported by the cell cycle ana-
lysis which showed very weak effects on the stromal cells,
only at 72 hrs at the highest concentration (Figure 6E-F).Discussion
Endometriosis is a benign disease of women during
reproductive age [17]; nevertheless, it is well known that
endometriosic cells display functional properties that are
typical of neoplastic cells, such as anti-apoptotic, invasive
and metastatic capacities [18,19]. In support to this obser-
vation, epidemiological studies have shown that there
exists an increased risk of different types of malignancies,
especially ovarian cancer and non-Hodgkin’s lymphoma in
women with endometriosis [20,21]. Nevertheless, it has
Figure 6 (See legend on next page.)
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Figure 6 Effects of purified recombinant protein of Homo Sapiens anti-Mullerian hormone (AMH) digested by Plasmin from human
plasma on endometriosis stromal and epithelial cell line. (A) pre-G1 fraction analysis of endometriosis stromal cells treated for 24-48-72 hrs
with the final concentrations of cleaved MIS as indicated. The data are shown in a time-dependent manner. (B) pre-G1 fraction analysis of
endometriosis stromal cells treated for 24-48-72 hrs with the final concentrations of cleaved MIS as indicated. The data are shown in a dose-dependent
manner. (C) Cell cycle analysis of endometriosis stromal cells treated for 24-48-72 hrs with the final concentrations of cleaved MIS as indicated. The data
are shown in a time-dependent manner. (D) Cell cycle analysis of endometriosis stromal cells treated for 24-48-72 hrs with the final concentrations of
cleaved MIS as indicated. The data are shown in a dose-dependent manner. (E) pre-G1 fraction analysis of endometriosis epithelial cells treated for
24-48-72 hrs with 1000 ng/mLof cleaved MIS. The data are shown in a time-dependent manner. (F) Cell cycle analysis of endometriosis epithelial cells
treated for 24-48-72 hrs with 1000 ng/mLof cleaved MIS. The data are shown in a time-dependent manner.
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plastic nevi, melanoma, and breast cancer [22,23]. Finally,
several histological and genetic studies have indicated that
endometriosis may transform into cancer or that it could
be considered a precursor of cancer [24]. Recently, it has
been demonstrated by Wang et al., that adult human
endometrium has a functional AMH/AMHRII signal
transduction system and that the activation of this system
is able to negatively regulate cellular viability in cultured
endometrial cells [12]. Indeed, the exact biological role of
AMH in adult females is unclear. The most well recog-
nized function in adult is its involvement in recruitment
and selection of initial primordial follicles [25]. In fact,
there exists a plethora of research articles on the use of
AMH serum level as a sensitive marker to assess the ovar-
ian reserve [26]. However, consistently with the work by
Wang et al. [12], several papers have shown a part for
AMH as a regulator of cell growth in cells and tissues of
Mullerian origins, such as endometrial, ovarian, cervical
and breast tissues and a role for AMH as potential thera-
peutic factor in tumors originating from these tissues has
been proposed [27-31]. Recently, two independent research
groups have demonstrated that the AMH system is active
also in endometriosic cells in vitro and that it acts as a
negative regulator of cell cycle and cell viability [32,33].
In this study we have shown that AMH protein is clearly
expressed in endometriosis glands in humans; that it is
also expressed together with its receptor AMH RII in our
in vitro model of endometriosis; and that it is able to
inhibit cell proliferation and to induce apoptosis in endo-
metriosis cells, both epithelial and stromal. Several experi-
mental studies have revealed that AMH is strongly
activated by cleavage [34]. In fact, the C-terminal fragment
contains the conserved TGFβ domain [35] and the cleav-
age is necessary for efficient receptor binding [36]. Con-
sistent with these observation, it has been reported that
the plasmin-digested AMH is more active in cultured
human endometrial cell lines [15]. In our experimental
setting, we have been able to demonstrate that cleaved
AMH is effective in inhibiting cell proliferation in endo-
metriosis cells. Moreover, this cleaved form of AMH is
able to inhibit most of the CYP19 activity in endometriosis
cells, as it has been already shown for cultured granulosa
lutein cells [15]. Several studies have suggested thatendometriosis implants are able to produce estrogen
de novo from cholesterol [37]. Therefore, endogenous
steroidogenic genes in local estradiol biosynthesis in endo-
metriosis are crucial for the survival of these implants.
Based on this rationale, it has been recently proposed the
use of aromatase inhibitors as a novel treatment of endo-
metriosis. Our experimental data demonstrate, indeed, that
AMH treatment is able to inhibit CYP19 activity, that is
the key enzyme in humans for the conversion of C19
steroids to estrogens [38], thus suggesting a possible bio-
logical explanation of the effects of this hormone on cell
growth and apoptosis.
Conclusions
The clinical and therapeutic implications of this observa-
tion are straightforward. In fact, all current endometriosis
treatments, including surgical and medical strategies, have
high recurrence rates of up to 45% [17]. The data pro-
duced suggest a possible use of AMH as therapeutic
agents in endometriosis. Additional functional studies
both in vitro and in vivo are necessary in order to define
applicable therapeutic modalities.
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